

3 August 2022

Incidence and Treatment of Different Types of Cancer in the UK

We are investigating the incidence and treatment of different types of cancer in the UK. We would greatly appreciate if you could answer the below questions:

1. How many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents:

• Carboplatin (monotherapy or in combination with 5-FU)	6
• Cisplatin (monotherapy or in combination with 5-FU)	20
• Cetuximab with/without chemotherapy	<5
• Cetuximab with radiotherapy	<5
• Pembrolizumab monotherapy	13
• Pembrolizumab with chemotherapy	<5
• Nivolumab	5
• Docetaxel (monotherapy or in combination with 5-FU)	<5
• Fluorouracil (5FU)	<5
• Radiotherapy only	50
Radical radiotherapy alone	38
Palliative radiotherapy alone	12
• Other Cisplatin + XRT - 7, Carboplatin + Etoposide - <5, Gemcitabine - <5	

Use of <5 (less than five): We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

2. For the patients treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the therapies listed in the first question, please provide:

• Total number of head and neck cancer patients

Total treated with SACT: 53

• Number of locally advanced head and neck cancer patients

Information unavailable

• Number of unresectable recurrent and/or metastatic head and neck cancer patients

Information unavailable

3 August 2022

3. How many Urothelial cancer patients have been treated in the past 3 months with the following agents:

- Avelumab <5
- Atezolizumab 10
- Carboplatin with Gemcitabine 10
- Carboplatin single or in any other combination <5
- Cisplatin with Gemcitabine 9
- Cisplatin single or in any other combination <5
- Nivolumab <5
- Pembrolizumab <5
- Any other regimen including Paclitaxel <5
- Any other chemotherapy regimen Fluorouracil + Mitomycin C <5
- Other active systemic anti-cancer therapy [please state] <5
- Palliative care only - Information unavailable

4. Does your Trust participate in any ongoing clinical trials for the treatment of head and neck cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Active studies

COMPARE: Phase III randomised controlled trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer. Open to recruitment - **<5 patients recruited to date.**

CCS1477-01: An open-label phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced solid/metastatic tumours. Although not specific to H&N, **<5 head and neck cancer patients have been recruited to this early phase study.**

Studies in active set-up

ADEPT Trial: Accelerating the development and implementation of personalised treatments of DNA Damage Response agents and radiotherapy +/- immunotherapy for head and neck squamous cell cancer.

BAYER 21343: An open-label, phase Ib, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics and efficacy of the Aryl Hydrocarbon Receptor Inhibitor (AhRi) Bay 2416964 in combination with Pembrolizumab in participants with advanced solid tumours.

The following study *may* proceed with set-up pending confirmation of PET capacity – decision will be made Sept 2022:

PETNECK 2: PET-CT-guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head neck cancer.